Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5 Ianalumab Phase II data in immune thrombocytopenia and ...

Health disparities in Canada go beyond individual health issues - they underscore deeper societal injustices that undermine our social fabric. These inequities highlight the existence of systemic ...

• Applications are now being accepted, with $500,000 in grants to be awarded to projects focused on improving health equity in Canada Montreal, Quebec, May 14, 2025 – Novartis Pharmaceuticals Canada ...

While the exact reason for this gender imbalance remains unknown, researchers are exploring contributing factors, including hormones, environmental triggers, and antibody levels. 3 Nevertheless, the ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Utforsk mulighetene hos Novartis og Sandoz her. Se mer informasjon om stillinger hos Novartis Gene Therapies på GTx Career Search.

Explore opportunities with Novartis below.

Job Title Sort ascending Business Location Site Date Posted Praktikant Medical ab 112025 Early Career (Befristet), Full time Universal Hierarchy Node Germany Nuremberg (Non-Sales Force) (Novartis ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

The company will make a total investment of $23B over the next five years, creating: Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities New ...